[8-K] Virios Therapeutics, Inc. Common Stock Reports Material Event
Dogwood Therapeutics, Inc. furnished a press release reporting its results of operations for the quarter ended June 30, 2025, which is included as Exhibit 99.1 and is incorporated by reference into Item 2.02 of this Current Report.
The Form notes the information is being furnished, not filed, so it is not subject to Section 18 liability and is not incorporated by reference into other filings. The registrant identifies as an emerging growth company and did not check the box indicating an election to forgo the extended transition period. The company’s common stock trades on the Nasdaq Capital Market under ticker DWTX. The report is signed by Angela Walsh, Chief Financial Officer, Corporate Secretary and Treasurer.
Dogwood Therapeutics, Inc. ha pubblicato un comunicato stampa contenente i risultati operativi per il trimestre chiuso il 30 giugno 2025, incluso come Exhibit 99.1 e incorporato per riferimento nella voce 2.02 del presente Current Report.
Il modulo specifica che le informazioni sono fornite, non depositate, pertanto non sono soggette alla responsabilità ai sensi della Sezione 18 e non vengono incorporate per riferimento in altri depositi. Il registrante si identifica come emerging growth company e non ha selezionato la casella per rinunciare al periodo di transizione esteso. Le azioni ordinarie della società sono quotate sul Nasdaq Capital Market con il simbolo DWTX. Il rapporto è firmato da Angela Walsh, Direttore finanziario, Segretario societario e Tesoriere.
Dogwood Therapeutics, Inc. difundió un comunicado de prensa con sus resultados operativos correspondientes al trimestre concluido el 30 de junio de 2025, que se incluye como Exhibit 99.1 y se incorpora por referencia en el punto 2.02 de este Current Report.
El formulario señala que la información se ha proporcionado, no presentado, por lo que no está sujeta a la responsabilidad prevista en la Sección 18 y no se incorpora por referencia en otros registros. El registrante se identifica como emerging growth company y no marcó la casilla para renunciar al período de transición ampliado. Las acciones ordinarias de la compañía cotizan en el Nasdaq Capital Market bajo el símbolo DWTX. El informe está firmado por Angela Walsh, Directora financiera, Secretaria corporativa y Tesorera.
Dogwood Therapeutics, Inc.는 2025년 6월 30일로 종료된 분기 실적을 알리는 보도자료를 제공했으며, 해당 자료는 Exhibit 99.1로 포함되어 본 Current Report의 항목 2.02에 참조로 통합되었습니다.
해당 양식은 정보가 제공되었으며, 제출된 것이 아님을 명시하고 있어 섹션 18에 따른 책임의 대상이 아니며 다른 제출 서류에 참조로 통합되지 않습니다. 등록자는 자신을 emerging growth company로 식별했으며 확대 전환 기간을 포기하는 선택란을 선택하지 않았습니다. 회사의 보통주는 Nasdaq Capital Market에 DWTX라는 티커로 거래됩니다. 이 보고서는 최고재무책임자 겸 법인 서기 및 재무담당인 Angela Walsh가 서명했습니다.
Dogwood Therapeutics, Inc. a diffusé un communiqué de presse faisant état de ses résultats d'exploitation pour le trimestre clos le 30 juin 2025, qui est inclus en tant que Exhibit 99.1 et incorporé par renvoi à l'Item 2.02 de ce Current Report.
Le formulaire indique que les informations ont été fournies, non déposées, et ne sont donc pas soumises à la responsabilité prévue par la Section 18 et ne sont pas incorporées par renvoi dans d'autres dépôts. Le déclarant se qualifie d'emerging growth company et n'a pas coché la case indiquant avoir renoncé à la période de transition prolongée. Les actions ordinaires de la société sont négociées sur le Nasdaq Capital Market sous le symbole DWTX. Le rapport est signé par Angela Walsh, directrice financière, secrétaire générale et trésorière.
Dogwood Therapeutics, Inc. hat eine Pressemitteilung mit den Betriebsergebnissen für das Quartal zum 30. Juni 2025 veröffentlicht, die als Exhibit 99.1 beigefügt und durch Verweis in Punkt 2.02 dieses Current Reports aufgenommen ist.
Im Formular wird angegeben, dass die Informationen bereitgestellt, nicht eingereicht wurden; sie unterliegen daher nicht der Haftung nach Section 18 und werden nicht per Verweis in andere Einreichungen übernommen. Der Registrant bezeichnet sich als emerging growth company und hat das Feld für den Verzicht auf die verlängerte Übergangsfrist nicht angekreuzt. Die Stammaktien der Gesellschaft werden am Nasdaq Capital Market unter dem Tickersymbol DWTX gehandelt. Der Bericht ist von Angela Walsh, Finanzchefin, Unternehmenssekretärin und Schatzmeisterin, unterzeichnet.
- Press release announcing Q2 2025 results was furnished and included as Exhibit 99.1, indicating timely disclosure of operating results to the market.
- Company ticker and listing disclosed: common stock trades on the Nasdaq Capital Market under DWTX, providing clear market identification.
- No financial figures or operational metrics are included in the body of this Form 8-K, so the filing alone does not allow assessment of performance.
- Information is furnished, not filed, which limits Section 18 liability and means the content is not automatically incorporated by reference into other filings.
Insights
TL;DR: This 8-K furnishes Q2 2025 results via an attached press release; no financial figures appear in the 8-K itself, so market impact depends on Exhibit 99.1.
The filing merely furnishes a press release announcing results for the quarter ended June 30, 2025, and explicitly states the information is furnished, not filed. Because this Form 8-K contains no financial metrics or operational detail, investors and analysts cannot assess performance from the filing alone. Material implications therefore hinge entirely on the content of Exhibit 99.1; until that exhibit is reviewed, valuation or guidance impacts cannot be determined from this 8-K.
TL;DR: The disclosure is procedural: the company furnished a press release and preserved the reduced liability associated with furnishing rather than filing.
The registrant’s choice to furnish rather than file the press release limits Section 18 liability and prevents automatic incorporation into future filings. The form also indicates the company is an emerging growth company and did not elect to forgo the extended transition period for new accounting rules. These are routine governance and disclosure decisions with no standalone adverse governance signals in the text provided.
Dogwood Therapeutics, Inc. ha pubblicato un comunicato stampa contenente i risultati operativi per il trimestre chiuso il 30 giugno 2025, incluso come Exhibit 99.1 e incorporato per riferimento nella voce 2.02 del presente Current Report.
Il modulo specifica che le informazioni sono fornite, non depositate, pertanto non sono soggette alla responsabilità ai sensi della Sezione 18 e non vengono incorporate per riferimento in altri depositi. Il registrante si identifica come emerging growth company e non ha selezionato la casella per rinunciare al periodo di transizione esteso. Le azioni ordinarie della società sono quotate sul Nasdaq Capital Market con il simbolo DWTX. Il rapporto è firmato da Angela Walsh, Direttore finanziario, Segretario societario e Tesoriere.
Dogwood Therapeutics, Inc. difundió un comunicado de prensa con sus resultados operativos correspondientes al trimestre concluido el 30 de junio de 2025, que se incluye como Exhibit 99.1 y se incorpora por referencia en el punto 2.02 de este Current Report.
El formulario señala que la información se ha proporcionado, no presentado, por lo que no está sujeta a la responsabilidad prevista en la Sección 18 y no se incorpora por referencia en otros registros. El registrante se identifica como emerging growth company y no marcó la casilla para renunciar al período de transición ampliado. Las acciones ordinarias de la compañía cotizan en el Nasdaq Capital Market bajo el símbolo DWTX. El informe está firmado por Angela Walsh, Directora financiera, Secretaria corporativa y Tesorera.
Dogwood Therapeutics, Inc.는 2025년 6월 30일로 종료된 분기 실적을 알리는 보도자료를 제공했으며, 해당 자료는 Exhibit 99.1로 포함되어 본 Current Report의 항목 2.02에 참조로 통합되었습니다.
해당 양식은 정보가 제공되었으며, 제출된 것이 아님을 명시하고 있어 섹션 18에 따른 책임의 대상이 아니며 다른 제출 서류에 참조로 통합되지 않습니다. 등록자는 자신을 emerging growth company로 식별했으며 확대 전환 기간을 포기하는 선택란을 선택하지 않았습니다. 회사의 보통주는 Nasdaq Capital Market에 DWTX라는 티커로 거래됩니다. 이 보고서는 최고재무책임자 겸 법인 서기 및 재무담당인 Angela Walsh가 서명했습니다.
Dogwood Therapeutics, Inc. a diffusé un communiqué de presse faisant état de ses résultats d'exploitation pour le trimestre clos le 30 juin 2025, qui est inclus en tant que Exhibit 99.1 et incorporé par renvoi à l'Item 2.02 de ce Current Report.
Le formulaire indique que les informations ont été fournies, non déposées, et ne sont donc pas soumises à la responsabilité prévue par la Section 18 et ne sont pas incorporées par renvoi dans d'autres dépôts. Le déclarant se qualifie d'emerging growth company et n'a pas coché la case indiquant avoir renoncé à la période de transition prolongée. Les actions ordinaires de la société sont négociées sur le Nasdaq Capital Market sous le symbole DWTX. Le rapport est signé par Angela Walsh, directrice financière, secrétaire générale et trésorière.
Dogwood Therapeutics, Inc. hat eine Pressemitteilung mit den Betriebsergebnissen für das Quartal zum 30. Juni 2025 veröffentlicht, die als Exhibit 99.1 beigefügt und durch Verweis in Punkt 2.02 dieses Current Reports aufgenommen ist.
Im Formular wird angegeben, dass die Informationen bereitgestellt, nicht eingereicht wurden; sie unterliegen daher nicht der Haftung nach Section 18 und werden nicht per Verweis in andere Einreichungen übernommen. Der Registrant bezeichnet sich als emerging growth company und hat das Feld für den Verzicht auf die verlängerte Übergangsfrist nicht angekreuzt. Die Stammaktien der Gesellschaft werden am Nasdaq Capital Market unter dem Tickersymbol DWTX gehandelt. Der Bericht ist von Angela Walsh, Finanzchefin, Unternehmenssekretärin und Schatzmeisterin, unterzeichnet.
FAQ
What did Dogwood Therapeutics (DWTX) disclose in this Form 8-K?
Does this 8-K include financial results or metrics for Q2 2025?
Is the information in the 8-K considered filed with the SEC?
What exchange and ticker does Dogwood Therapeutics use?
Is Dogwood Therapeutics an emerging growth company?
Who signed the Form 8-K for Dogwood Therapeutics?
